Effect of inescapable stress in rodent models of depression and posttraumatic stress disorder on CRH and vasopressin immunoreactivity in the hypothalamic paraventricular nucleus

Acta Physiologica Hungarica

Volumn 100, Issue 4, 2013, Pages 395-410

  Mironova, Vera ^a   Rybnikova, E ^a   Pivina, S ^a  

^a PAVLOV INSTITUTE OF PHYSIOLOGY   (Russian Federation)

Author keywords

animal models; anxiety; corticotropin releasing hormone; depression; hypothalamic paraventricular nucleus; vasopressin

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; VASOPRESSIN; VASOPRESSIN DERIVATIVE;

ANIMAL MODEL; ARTICLE; DEPRESSION; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; NEUROENDOCRINE DISEASE; NONHUMAN; POSTTRAUMATIC STRESS DISORDER; RAT; STRESS; ANIMAL; ANXIETY DISORDER; DISEASE MODEL; EXERCISE; IMMUNOHISTOCHEMISTRY; LEARNED HELPLESSNESS; MALE; MENTAL STRESS; METABOLISM; PATHOPHYSIOLOGY; PSYCHOLOGY; WISTAR RAT;

ANIMALS; ANXIETY DISORDERS; CORTICOTROPIN-RELEASING HORMONE; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; HELPLESSNESS, LEARNED; IMMUNOHISTOCHEMISTRY; MALE; PARAVENTRICULAR HYPOTHALAMIC NUCLEUS; RATS; RATS, WISTAR; RESTRAINT, PHYSICAL; STRESS DISORDERS, POST-TRAUMATIC; STRESS, PSYCHOLOGICAL; VASOPRESSINS;

EID: 84890401903     PISSN: 0231424X     EISSN: 15882683     Source Type: Journal    
DOI: 10.1556/APhysiol.100.2013.4.4     Document Type: Article

References (63)

1. Aguilera G, Rabadan-Deihl C: Vasopressinergic regulation of the hipothalamic-pituitary-adrenal axis: implications for stress adaptation. Regul. Peptides 96, 23-29 (2000)
2. Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB: The role of corticotropin-releasing factor in depression and anxiety disorders. J. Endocrinol. 160, 1-12 (1999)
3. Baker DG, West SA, Nicholson WE, Ekhator NN, Kaskow JW, Hill KK, Bruce AB, Orth DN, Geracioti Jr. TD: Serial CSF corticotropin-releasing hormone levels and adrenocortical activity in combat veterans with posttraumatic stress disorder. Am. J. Psychiat. 156, 585-588 (1999)
4. Bartanusz V, Jezova D, Bertinin LT, Tilders FJH, Aubry J, Kiss JZ: Stress-induced increase in vasopressin and corticotropin-releasing factor expression in hypophysiotrophic paraventricular neurons. Endocrinology 132, 895-901 (1993)
5. Bremner JD, Licinio J, Darnell A, Krystal JH, Owens MJ, Southwick SM, Nemeroff CB, Charney DS: Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am. J. Psychiat. 154, 624-629 (1997)
6. Campbell DG, Felker BL, Liu CF, Yano EM, Kirchner JE, Chan D, Rubenstein LV, Chaney EF: Prevalence of depression-PTSD comorbidity: implications for clinical practice guidelines and primary care-based interventions. J. Gen. Intern. Med. 22, 711-718 (2007)
7. Carroll BT: The dexamethazone suppression test for melancholia. Brit. J. Psychiat. 140, 292-304 (1982)
8. Chaki S, Nakazato A, Kennis L, Nakamura M, Mackie C, Sugiura M, Vinken P, Ashton D, Langlois X, Steckler T: Anxiolytic-and antidepressant-like profile of a new CRF1 receptor antagonist, R278995/CRA0450. Eur. J. Pharmacol. 485, 145-158 (2004)
9. Chappell PB, Smith MA, Kilts CD, Bissette G, Ritchie J, Anderson C, Nemeroff CB: Alterations in corticotropin-releasing factor-like immunoreactivity in discrete rat brain regions after acute and chronic stress. J. Neurosci. 6, 2908-2914 (1986)
10. De Kloet CS, Vermetten E, Geuze E, Wiegant VM, Westenberg HG: Elevated plasma arginine vasopressin levels in veterans with posttraumatic stress disorder. J. Psychiatr. Res. 2, 192-198 (2008)
11. De Kloet CS, Vermetten E, Heijnen CJ, Geuze E, Lentjes EG, Westenberg HG: Enhanced cortisol suppression in response to dexamethasone administration in traumatized veterans with and without posttraumatic stress disorder. Psychoneuroendocrinology 32, 215-226 (2007)
12. Dirks A, Groenink L, Bouwknecht JA, Hijzen TH, Van Der Gugten J, Ronken E, Verbeek JS, Veening JG, Dederen PJ, Korosi A, Schoolderman LF, Roubos EW, Olivier B: Overexpression of corticotropin-releasing hormone in transgenic mice and chronic stress-like autonomic and physiological alterations. Eur. J. Neurosci. 16, 1751-1760 (2002)
13. Dunn A, Berridge C: Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses. Brain Res. Rev. 15, 71-100 (1990)
14. Gold PW, Chrousos GP: Organization of the stress system and its disregulation in melancholic and atypical depression: high vs low CRH/NE states. Mol. Psychiatry 7, 254-275 (2002)
15. Griebel G, Stemmelin J, Gal CS, Soubrie P: Non-peptide vasopressin V1b antagonist as potential drugs for the treatment of stress-related disorders. Curr. Pharm. Design 11, 1549-1559 (2005)
16. Hatzinger M: Neuropeptides and hypothalamic-pituitary-adrenocortical (HPA) system: review of recent research strategies in depression. World J. Biol. Psychia. 1, 105-111 (2000)
17. Henkel V, Bussfeld P, Moller HJ, Hegerl U: Cognitive-behavioural theories of helplessness/hopelessness: valid models of depression? Eur. Arch. Psy. Clin. N. 252, 240-249 (2002)
18. Herman JP, Adams D, Prewitt C: Regulatory changes in neuroendocrine stress-integrative circuitry produced by a variable stress paradigm. Neuroendocrinology 61, 180-190 (1995)
19. Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23, 477-501 (2000)
20. Holsboer F, Ising M: Central CRH system in depression and anxiety-evidence from clinical studies with CRH1 receptor antagonists. European J. Pharmacol. 583, 350-357 (2008)
21. Jard S (1990): Vasopressin and oxytocin. In: Hormones: from Molecules to Disease, eds Baulllieu EE, Kelly PA, Chapmann and Hall, New York, pp. 282-302
22. Kalin NH: Behavioral effects of ovine corticotropin-releasing factor administered to rhesus monkeys. Fed. Proc. 44, 249-253 (1985)
23. Kaskow JW, Baker D, Geracioti TD: Corticotropin-releasing hormone in depression and post-traumatic stress disorder. Peptides 22, 845-851 (2001)
24. Keck ME: Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety. Amino Acids 31, 241-250 (2006)
25. Kehne J, De Lombaert S: Non-peptidic CRF1 receptor antagonists for the treatment of anxiety, depression and stress disorders. Curr. Drug Targets CNS Neurol. Disord. 1, 467-493 (2002)
26. Keller J, Flores B, Gomez RG, Solvason HB, Kenna H, Williams GH, Schatzberg AF: Cortisol circadian rhythm alterations in psychotic major depression. Biol. Psychiat. 60, 275-281 (2006)
27. Kessler RC (2001): Comorbidity of depression and anxiety disorders. SSRIs in Depression and Anxiety, Second Edition, eds Montgomery SA, den Boer JA, John Wiley and Sons, Ltd.
28. Koob GF, Heinrichs SC, Pich EM, Menzaghi F, Baldwin H, Miczek K, Britton KT: The role of corticotropin-releasing factor in behavioural responses to stress. Ciba F. Symp. 172, 277-289 (1993)
29. Liberzon I, Krstov M, Young EA: Stress-restress: effects on ACTH and fast feedback. Psychoneuroendocrino. 22, 443-453 (1997)
30. Ma XM, Lightman S, Aguilera G: Vasopressin and corticotropin-releasing hormone gene responses to novel stress in rats adapted to repeated restraint. Endocrinology 140, 3623-3632 (1999)
31. Mason JW, Giller EL, Kosten TR, Ostroff RB, Podd L: Urinary free cortisol levels in posttraumatic stress disorder patients. J. Nerv. Ment. Dis. 174, 145-149 (1986)
32. Mlynarik M, Zelena D, Bagdy G, Makara GB, Jezova D: Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm. Behav. 51, 395-405 (2007)
33. Mortola JF, Liu JH, Gillin JC, Rasmussen DD, Yen SS: Pulsatile rhythms of adrenocorticotropin (ACTH) and cortisol in women with endogenous depression: evidence for increased ACTH pulse frequency. J. Clin. Endocr. Metab. 65, 962-968 (1987)
34. Muller MB, Landgraf R, Keck ME: Vasopressin, major depression and hypothalamic-pituitary-adrenocortical desensitization. Biol. Psychiat. 48, 330-333 (2000)
35. Nakase S, Kitayama I, Soya H, Hamanaka K, Nomura J: Increased expression of magnocellular arginine vasopressin mRNA in paraventricular nucleus of stress-induced depression-model rats. Life Sci. 63, 23-31 (1998)
36. Norman TR: Prospects for the treatment of depression. Aust. N.Z. J. Psychiarty 40, 394-401 (2006)
37. Oquendo MA, Echavarria G, Galfalvy HC, Grunebaum MF, Burke I, Barrera A, Cooper TB, Malone KM, Mann JJ: Lower cortisol levels in depressed patients with comorbid posttraumatic stress disorder. Neuropsychopharmacol. 28, 591-598 (2003)
38. Ordyan NE, Pivina SG, Rakitskaya VV, Shalyapina VG: The neonatal glucocorticoid treatment produced long-term changes of the pituitary-adrenal function in brain corticosteroid receptors in rats. Steroids 66, 883-888 (2001)
39. Paxinos G, Watson C (1997): The rat brain in stereotaxic coordinates. Academic Press, San Diego, CA
40. Purba JS, Hoogendijk WJG, Hofman MA, Swaab DF: Increased number of vasopressin-and oxytocin-expressing neurons in the paraventricular nucleus of the hypothalamus in depression. Arch. Gen. Psychiat. 53, 137-143 (1996)
41. Raadsheer FC, Hoogendijk WJG, Stam FS, Tilders FJH, Swaab DF: Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60, 433-436 (1994)
42. Raone A, Cassanelli A, Scheggi S, Rauggi R, Danielli B, De Montis MG: Hypothalamus-pituitary-adrenal modifications consequent to chronic stress exposure in an experimental model of depression in rats. Neuroscience 146, 1734-1742 (2007)
43. Ring RH: The central vasopressinergic system: examining the opportunities for psychiatric drug development. Curr. Pharm. Design 11, 205-225 (2005)
44. Rybnikova E, Mironova V, Pivina S, Tulkova E, Ordyan N, Nalivaeva N, Turner A, Samoilov M: Involvement of hypothalamic-pituitary-adrenal axis in the antidepressant-like effect of mild hypoxic preconditioning in rats. Psychoneuroendocrino. 32, 813-823 (2007)
45. Rybnikova E, Mironova V, Pivina S, Tulkova E, Ordyan N, Vataeva L, Vershinina E, Abritalin E, Kolchev A, Nalivaeva N, Turner A, Samoilov M: Antidepressant-like effect of mild hypoxia preconditioning in the learned helplessness model in rats. Neurosci. Lett. 417, 234-239 (2007)
46. Sawchenko PE, Swanson LW: Localization, colocalization, and plasticity of corticotropin-releasing factor immunoreactivity in rat brain. Fed. Proc. 44, 221-227 (1985)
47. Scott L, Dinan TG: Vasopressin and regulation of hypothalamic-pituitary- adrenal axis function: implications for the pathophysiology of depression. Life Sci. 62, 1985-1998 (1998)
48. Scott L, Dinan TG: Vasopressin as a target for antidepressant development: an assessment of available evidence. J. Affect. Disorders 72, 113-124 (2002)
49. Smagin GN, Heinrics SC, Dunn AJ: The role of CRH in behavioral responses to stress. Peptides 22, 713-724 (2001)
50. Stenzel-Poore MP, Heinrichs SC, Rivest S, Koob G, Vale WW: Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J. Neurosci. 14, 2579-2584 (1994)
51. Swanson LW (1987): The hypothalamus. In: Handbook of Chemical Neuroanatomy, vol. 5: Integrated systems of the CNS, part I. Hypothalamus, hippocampus, amygdala, retina, eds Björklund A, Hökfelt T, Swanson LW, Elsevier Science Publishers, Amsterdam-New York-Oxford, pp. 1-124
52. Swanson LW, Sawchenko PE: Paraventricular nucleus: a site for the integration of neuroendocrine and autonomic mechanisms. Neuroendocrinology 31, 410-417 (1980)
53. Tichomirowa MA, Keck ME, Schneider HJ, Paez-Pereda M, Runner U, Holsboer F, Stalla GK: Endocrine disturbances in depression. J. Endocrinol. Invest. 28, 89-99 (2005)
54. Tsigos C, Chrousos GP: Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J. Psychosom. Res. 53, 865-871 (2002)
55. Turnbull AV, Rivier C: Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, related peptides. P. Soc. Exp. Biol. Med. 215, 1-10 (1997)
56. Uys JD, Stein DJ, Daniels WM, Harvey BH: Animal models of anxiety disorders. Curr. Psychiatry Rep. 5, 274-281 (2003)
57. Watson S, Mackin P: HPA axis function in mood disorders. Psychiatry 5, 166-170 (2006)
58. Weisberg RB, Bruce SE, Machan JT, Kessler RC, Culpepper L, Keller MB: Nonpsychiatric illness among primary care patients with trauma histories and posttraumatic stress disorder. Psychiat. Serv. 53, 848-854 (2002)
59. Wigger A, Sanchez MM, Mathys KC, Ebner K, Frank E, Liu D, Kresse A, Neumann ID, Holsboer F, Plotsky PM, Landgraf R: Alterations in central neuropeptide expression, release, and receptor binding in rats bred for high anxiety: critical role of vasopressin. Neuropsychopharmacol. 29, 1-14 (2004)
60. Yehuda R: Advances in understanding neuroendocrine alterations in PTSD and their therapeutic implications. Ann. NY Acad. Sci. 1071, 137-166 (2006)
61. Yehuda R, Antelman SM: Criteria for evaluating animal models of post traumatic stress disorder. Biol. Psychiat. 33, 479-486 (1993)
62. Yehuda R, Southwick SM, Krystal JH, Bremner D, Charney DS, Mason JW: Enhanced suppression of cortisol following dexamethasone administration in posttraumatic stress disorder. Am. J. Psychiat. 150, 83-86 (1993)
63. Zhukov DA: The dexamethasone suppression test in genetically different rats exposed to inescapable and escapable electric shocks. Psychoneuroendocrino. 18, 467-474 (1993)